eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | tuberous sclerosis |
| Comorbidity | C0206633|angiomyolipoma |
| Sentences | 20 |
| PubMedID- 24522027 | Re: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (exist-2): a multicentre, randomised, double-blind, placebo-controlled trial. |
| PubMedID- 24813310 | In general, sirolimus is an effective and safe therapy for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. |
| PubMedID- 23312829 | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (exist-2): a multicentre, randomised, double-blind, placebo-controlled trial. |
| PubMedID- 23054313 | Purpose: renal angiomyolipoma in patients with tuberous sclerosis can cause life-threatening bleeding. |
| PubMedID- 26156073 | Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. |
| PubMedID- 20551552 | An unusual case of multifocal renal angiomyolipoma associated with tuberous sclerosis and presenting as massive intra abdominal hemorrhage is reported. |
| PubMedID- 25884947 | Rapamycin belongs to the class of macrocyclic immunosuppressive drugs used in preventing rejection after organ transplantation, topical treatment of facial angiofibromas, renal angiomyolipoma, brain tumors associated with tuberous sclerosis and chemotherapy for a variety of cancers. |
| PubMedID- 24729041 | The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial exist-1. |
| PubMedID- 26279726 | Composite renal cell carcinoma and angiomyolipoma in a patient with tuberous sclerosis: a diagnostic dilemma. |
| PubMedID- 24777052 | Inhibition of mtor with rapalogs has shown clinical efficacy against some solid tumors, including everolimus for angiomyolipoma associated with tuberous sclerosis, metastatic renal cell carcinoma, breast cancer, or pancreatic neuroendocrine carcinomas and temsirolimus for renal cell carcinoma [11]–[14]. |
| PubMedID- 24854916 | Objective: to explore the clinical characteristics, diagnosis, treatment and outcomes of renal angiomyolipoma (raml) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 24833837 | Twenty-thirty percent of renal angiomyolipoma are associated with tuberous sclerosis. |
| PubMedID- 23642941 | Commentary on: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (exist-2): a multicentre, randomised, double-blind, placebo-controlled trial. |
| PubMedID- 24170533 | Purpose: to describe the role of mammalian target of rapamycin (mtor) inhibition in the treatment of tuberous sclerosis complex (tsc) patients with renal angiomyolipoma in relation to available clinical data and clinical practice guidance for the nurse practitioner (np). |
| PubMedID- 25580845 | Renal epithelioid angiomyolipoma in a patient with tuberous sclerosis. |
| PubMedID- 24159414 | But bladder angiomyolipoma associated with tuberous sclerosis has not been seen in the literature. |
| PubMedID- 23312828 | Everolimus for renal angiomyolipoma in tuberous sclerosis. |
| PubMedID- 23689226 | Additional oncology indications for everolimus include renal angiomyolipoma with tuberous sclerosis complex and subependymal giant-cell astrocytoma. |
| PubMedID- 21525172 | Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. |
| PubMedID- 24640214 | Bilateral renal angiomyolipoma in tuberous sclerosis is a rare entity. |
Page: 1